{"id":"W4220925708","doi":"10.1136/rmdopen-2021-002138","title":"Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study","year":2022,"lang":"en","type":"article","venue":"RMD Open","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Cilag; Regeneron Pharmaceuticals; UCB Pharma; Ablynx; Gilead Sciences; Eisai; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Certolizumab pegol; Axial spondyloarthritis; Radiography; Term (time); Internal medicine; Sacroiliitis; Ankylosing spondylitis; Medical physics; Physical therapy; Radiology; Nuclear medicine; Adalimumab; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006621026,0.0007659953,0.001592416,0.0003115649,0.0004612749,0.00104683,0.0005545602,0.001376192,0.0009611497],"category_scores_gemma":[0.002340757,0.0002664906,0.002027401,0.000431176,0.0006920587,0.000731898,0.0004452435,0.002033336,0.0003054112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006776939,"about_ca_system_score_gemma":0.001142778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000651947,"about_ca_topic_score_gemma":0.0008501881,"domain_scores_codex":[0.9987376,0.0006192168,0.0001149815,0.0001203648,0.0002345922,0.0001731856],"domain_scores_gemma":[0.9963865,0.0006989948,0.001446071,0.000283663,0.0004398171,0.0007448479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7087692,0.02021479,0.1203191,0.001240965,0.004601487,0.0004134495,0.0005453783,0.002343521,0.01653097,0.0001596663,0.003654613,0.1212069],"study_design_scores_gemma":[0.2080635,0.4023004,0.3770997,0.0001970717,0.002537112,0.0007405467,0.0001717835,0.00209973,0.003370235,0.0002215931,0.003099383,0.00009901896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942643,0.003655089,0.0002658924,0.0001817704,0.00002771191,0.0003028301,0.0007520012,0.00002239215,0.0005279991],"genre_scores_gemma":[0.9953945,0.001157278,0.0004975063,0.0004148319,0.00008279699,0.0003131737,0.001841857,0.000007505677,0.0002904354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006621026,"threshold_uncertainty_score":0.03501576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02632555762703032,"score_gpt":0.3369773064063954,"score_spread":0.3106517487793651,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}